US Alzheimer Drug Pipeline Analysis
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this, the people aged 65 and above accounted for 5.2 million and at least 200,000 patients were younger than 65 with early?onset of Alzheimer’s. It has been observed that almost 1 in 8 people coming under the 65+ age group are patients of Alzeimer’s disease. Amongst the population in the 80+ age group, almost 45% have been detected with Alzeimer’s disease.
There exists strong competition in the Azheimer’s disease market in the US. Due to this, the market is open to new and savvy companies. Given that there is a continuous rise in the ageing population and an expected exponential increase in Alzheimer’s disease cases, these new entrants have the opportunity to capture a major share in the market through their efficient therapies and drugs. Thus, a better understanding of the underlying biology by the new entrants would lead to many new branches of treatment in different stages of clinical testing.
“US Alzheimer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Alzheimer Drug Pipeline Analysis” research report:
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this, the people aged 65 and above accounted for 5.2 million and at least 200,000 patients were younger than 65 with early?onset of Alzheimer’s. It has been observed that almost 1 in 8 people coming under the 65+ age group are patients of Alzeimer’s disease. Amongst the population in the 80+ age group, almost 45% have been detected with Alzeimer’s disease.
There exists strong competition in the Azheimer’s disease market in the US. Due to this, the market is open to new and savvy companies. Given that there is a continuous rise in the ageing population and an expected exponential increase in Alzheimer’s disease cases, these new entrants have the opportunity to capture a major share in the market through their efficient therapies and drugs. Thus, a better understanding of the underlying biology by the new entrants would lead to many new branches of treatment in different stages of clinical testing.
“US Alzheimer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Alzheimer Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 28
- Preclinical: 106
- Phase 0: 3
- Phase-I: 36
- Phase-I/II: 2
- Phase-II: 25
- Phase-II/III: 3
- Phase-III: 8
- Preregistration: 2
- Marketed: 6
1. US ALZHEIMER DISEASE MARKET OVERVIEW
2. ALZHEIMER DRUG CLINICAL PHASE: RESEARCH
2.1 Overview
2.2 Alzheimer Drug Profile in Clinical Phase
3. ALZHEIMER DRUG CLINICAL PHASE: PRECLINICAL
3.1 Overview
3.2 Alzheimer Drug Profile in Clinical Phase
4. ALZHEIMER DRUG CLINICAL PHASE: PHASE
4.1 Overview
4.2 Alzheimer Drug Profile in Clinical Phase
5. ALZHEIMER DRUG CLINICAL PHASE: PHASE I
5.1 Overview
5.2 Alzheimer Drug Profile in Clinical Phase
6. ALZHEIMER DRUG CLINICAL PHASE: PHASE I/II
6.1 Overview
6.2 Alzheimer Drug Profile in Clinical Phase
7. ALZHEIMER DRUG CLINICAL PHASE: PHASE II
7.1 Overview
7.2 Alzheimer Drug Profile in Clinical Phase
8. ALZHEIMER DRUG CLINICAL PHASE: PHASE II/III
8.1 Overview
8.2 Alzheimer Drug Profile in Clinical Phase
9. ALZHEIMER DRUG CLINICAL PHASE: PHASE III
9.1 Overview
9.2 Alzheimer Drug Profile in Clinical Phase
10. ALZHEIMER DRUG CLINICAL PHASE: PREREGISTRATION
10.1 Overview
10.2 Alzheimer Drug Profile in Clinical Phase
11. MARKETED ALZHEIMER DRUG
11.1 Overview
11.2 Marketed Alzheimer Drug Profile
EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:
Alternate Names
Originator & Owner
Collaborator
Technology Provider
Licensee
Highest Development Phase
Indications
Class
Mechanism of Action
ATC Code
Designated Brand Name
2. ALZHEIMER DRUG CLINICAL PHASE: RESEARCH
2.1 Overview
2.2 Alzheimer Drug Profile in Clinical Phase
3. ALZHEIMER DRUG CLINICAL PHASE: PRECLINICAL
3.1 Overview
3.2 Alzheimer Drug Profile in Clinical Phase
4. ALZHEIMER DRUG CLINICAL PHASE: PHASE
4.1 Overview
4.2 Alzheimer Drug Profile in Clinical Phase
5. ALZHEIMER DRUG CLINICAL PHASE: PHASE I
5.1 Overview
5.2 Alzheimer Drug Profile in Clinical Phase
6. ALZHEIMER DRUG CLINICAL PHASE: PHASE I/II
6.1 Overview
6.2 Alzheimer Drug Profile in Clinical Phase
7. ALZHEIMER DRUG CLINICAL PHASE: PHASE II
7.1 Overview
7.2 Alzheimer Drug Profile in Clinical Phase
8. ALZHEIMER DRUG CLINICAL PHASE: PHASE II/III
8.1 Overview
8.2 Alzheimer Drug Profile in Clinical Phase
9. ALZHEIMER DRUG CLINICAL PHASE: PHASE III
9.1 Overview
9.2 Alzheimer Drug Profile in Clinical Phase
10. ALZHEIMER DRUG CLINICAL PHASE: PREREGISTRATION
10.1 Overview
10.2 Alzheimer Drug Profile in Clinical Phase
11. MARKETED ALZHEIMER DRUG
11.1 Overview
11.2 Marketed Alzheimer Drug Profile
EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:
Alternate Names
Originator & Owner
Collaborator
Technology Provider
Licensee
Highest Development Phase
Indications
Class
Mechanism of Action
ATC Code
Designated Brand Name
